Skip to Content

'
Juan Fueyo, M.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director Brain Tumor Program-Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of Neuro-Oncology Experimental Research, Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Neurosurgery - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Regular Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Research Interests

  • Oncolytic adenoviruses
  • Cell cycle/apoptosis
  • Autophagy
  • p16/Rb/E2F-1 pathway
  • Molecular therapy
  • Gliomas
  • Cancer biology

My laboratory's projects primarily focus on the development of novel gene therapy strategies for the treatment of malignant gliomas. Specifically, I have been examining the mechanisms of cell- cycle control and cell death that are abrogated in brain tumors. Though working mostly on the P16/Rb (retinoblastoma)/E2F-1 pathway, we are also studying the role of p16, Rb, and E2F-1 as tumor suppressor genes in gliomas. In addition, I am in the process of determining whether conventional chemotherapeutics for gliomas can be enhanced when combined with gene therapy. Another related project involves the determination of proficient means of gene delivery using oncolytic viruses. In this regard, we have identified a replication-competent adenovirus (Delta- 24) that cannot bind the Rb protein, has a potent anticancer effect, and low toxicity in quiescent normal cells. The Delta-24 adenoviral construct is currently the target of a provisional patent and is being further realized into a future clinical trial for patients with malignant brain tumors. The focus of my laboratory over the next two years will be on improving the anticancer effect of oncolytic adenoviruses and the translation of those pre-clinical findings to the clinic setting.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Department of Neuro-Oncology - Research
Unit Number: 1002
Houston, TX 77030-4009
Room Number: BSRB, Rm S5.8316B
Phone: 713-834-6221
Fax: 713-745-0387
Email: jfueyo@mdanderson.org

Education & Training

Degree-Granting Education

1984 University Autonomous of Barcelona, Barcelona, Spain, MD, Medicine

Postgraduate Training

1994-1997 Research Fellowship, Experimental Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, AP Kyritsis
1985-1992 Clinical Residency, Neurology, University Autonomous of Barcelona, Barcelona, Spain

Experience/Service

Academic Appointments

Associate Professor (Tenure), Department of Neuro-Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2006-8/2012

Institutional Committee Activities

Member, GSBS Curriculum Committee, 9/2011-present
Chairman, Study Section Review Committee for Basic Research, IRG Committee Meeting, 9/2007-8/2008
Vice Chairman, Study Section Review Committee for Basic Research, IRG Committee Meeting, 9/2006-8/2007
Member, Study Section Review Committee for Basic Research, IRG Committee Meeting, 8/2005-9/2006
Member, Executive Committee, Brain Tumor Center, 7/2005-present
Member, Executive Committee, Department of Neuro-Oncology, 6/2005-present
Co-Chairman, Laboratory Research Subcommittee, Brain Tumor Center, 5/2005-2010
Co-Chairman, Educational Committee, Brain Tumor Center, 9/2002-8/2005

Honors and Awards

2012 Waun Ki Hong Award for Excellence Team Science [Delta-24 program], MD Anderson Cancer Center
2009 Nomination for the Waun Ki Hong Award for Excellence Team Science [Delta-24 program], The University of Texas M. D. Anderson Cancer Center
2003 The Peter A. Steck Memorial Award, The Pediatric Brain Tumor Foundation of the United States of America
1997 Best Presentation Award, European Neurological Society (ENS)
1995 Travel grant, American Association for Cancer Research (AACR)

Professional Memberships

American Academy of Neurology (AAN), Saint Paul, MN
Associated Member, 1996-present
American Association for Cancer Research (AACR), Philadelphia, PA
Member, 2004-present
American Association for the Advancement of Science (AAAS), Washington, DC
Member, 1999-present
Society for Neuro-Oncology (SNO), Houston, TX
Member, 2000-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Martín V, Sanchez-Sanchez AM, Herrera F, Gomez-Manzano C, Fueyo J, Alvarez-Vega MA, Antolín I, Rodriguez C. Melatonin-induced methylation of the ABCG2/BCRP promoter as a novel mechanism to overcome multidrug resistance in brain tumour stem cells. Br J Cancer 108(10):2005-12, 5/2013. e-Pub 4/2013. PMCID: PMC3670480.
2. Jiang H, White EJ, Ríos-Vicil CI, Xu J, Gomez-Manzano C, Fueyo J. Human Adenovirus Type 5 Induces Cell Lysis through Autophagy and Autophagy-Triggered Caspase Activity. J Virol 85(10):4720-9, 5/2011. e-Pub 3/2011. PMCID: PMC3126198.
3. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez de Munain A, Sampron N, Aramburu A, Tejada-Solís S, Vicente C, Odero MD, Bandrés E, García-Foncillas J, Idoate MA, Lang FF, Fueyo J, Gomez-Manzano C. Genetic and Epigenetic Modifications of Sox2 Contribute to the Invasive Phenotype of Malignant Gliomas. PLoS One 6(11):e26740, 2011. e-Pub 11/2011. PMCID: PMC3206066.
4. Piya S, White EJ, Klein SR, Jiang H, McDonnell TJ, Gomez-Manzano C, Fueyo J. The E1B19K Oncoprotein Complexes with Beclin 1 to Regulate Autophagy in Adenovirus-Infected Cells. PLoS One 6(12):e29467, 2011. e-Pub 12/2011. PMCID: PMC3248451.
5. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. Oncotarget 1(8):700-9, 12/2010. PMID: 21321379.
6. Jiang H, Martin V, Gomez-Manzano C, Johnson DG, Alonso M, White E, Xu J, McDonnell TJ, Shinojima N, Fueyo J. The RB-E2F1 Pathway Regulates Autophagy. Cancer Res 70(20):7882-93, 10/2010. e-Pub 8/2010. PMID: 20807803.
7. Dembinski JL, Spaeth EL, Fueyo J, Gomez-Manzano C, Studeny M, Andreeff M, Marini FC. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther 17(4):289-97, 4/2010. e-Pub 10/2009. PMID: 19876078.
8. Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF. Human Bone Marrow-Derived Mesenchymal Stem Cells for Intravascular Delivery of Oncolytic Adenovirus {Delta}24-RGD to Human Gliomas. Cancer Res 69(23):8932-40, 11/2009. e-Pub 11/2009. PMID: 19920199.
9. Martin V, Xu J, Pabbisetty SK, Alonso MM, Liu D, Lee OH, Gumin J, Bhat KP, Colman H, Lang FF, Fueyo J, Gomez-Manzano C. Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters. Oncogene 28(24):2358-63, 6/2009. e-Pub 5/2009. PMID: 19421150.
10. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, Aldape KD, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol 10(6):940-5, 12/2008. e-Pub 8/2008. PMID: 18708344.
11. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, Aldape KD, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity. Cancer Gene Ther 16(3). e-Pub 10/2008. PMID: 18927600.
12. Li JY, Wang H, May S, Song X, Fueyo J, Fuller GN, Wang H. Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas. J Neurooncol 88(1):11-7, 5/2008. e-Pub 2/2008. PMID: 18246408.
13. Alonso MM, Jiang H, Yokoyama T, Xu J, Bekele NB, Lang FF, Kondo S, Gomez-Manzano C, Fueyo J. Delta-24-RGD in combination with RAD001 induces enhanced anti-glioma effect via autophagic cell death. Mol Ther 16(3):487-93, 3/2008. e-Pub 2/2008. PMID: 18253154.
14. Lee OH, Xu J, Fueyo J, Alonso MM, Liu D, Martin V, Jiang H, Piao Y, Liu TJ, Gomez-Manzano C. Angiopoietin-2 decreases vascular endothelial growth factor expression by modulating HIF-1 alpha levels in glioma. Oncogene 27(9):1310-1314, 2/2008. e-Pub 8/2007. PMID: 17704802.
15. Alonso MM, Gomez-Manzano C, Bekele BN, Yung WK, Fueyo J. Adenovirus-based strategies overcome temozolomide resistance by silencing the 06-methylguanine-DNA methyltransferase promoter. Cancer Res 67(24):11499-504, 12/2007. PMID: 18089777.
16. Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67(22):11054-63, 11/2007. PMID: 18006852.
17. Jiang H, Gomez-Manzano C, Aoki H, Alonso MM, Knodo S, McCormick F, Xu J, Kondo Y, Bekele BN, Colman H, Lang FF, Fueyo J. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst 99(18):1410-4, 9/2007. e-Pub 9/2007. PMID: 17848677.
18. Alonso MM, Cascallo M, Gomez-Manzano C, Jiang H, Bekele BN, Perez-Gimenez A, Lang FF, Piao Y, Alemany R, Fueyo J. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo. Cancer Res 67(17):8255-63, 9/2007. PMID: 17804740.
19. Cascallo M, Alonso MM, Rojas JJ, Perez-Gimenez A, Fueyo J, Alemany R. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Mol Ther 15(9):1607-15, 9/2007. e-Pub 6/2007. PMID: 17579575.
20. Alonso MM, Gomez-Manzano C, Jiang H, Bekele NB, Piao Y, Yung WK, Alemany R, Fueyo J. Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14(8):756-761, 8/2007. e-Pub 6/2007. PMID: 17557108.
21. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, Aldape KD, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. Cancer Res 67(9):4005-4009, 5/2007. PMID: 17483310.
22. Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, Alonso MM, Gomez-Manzano C, Hung MC, Yung WK, Fueyo J. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 20:2603-5, 12/2006. PMID: 17065226.
23. Lee OH, Xu J, Fueyo J, Fuller GN, Aldape KD, Alonso MM, Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. Mol Cancer Res 4:915-26, 12/2006. PMID: 17189382.
24. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, Aldape KD, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia 8(5):419-28, 5/2006. PMID: 16790091.
25. Gomez-Manzano C, Alonso MM, Yung WK, McCormick F, Curiel DT, Lang FF, Jiang H, Bekele BN, Zhou X, Alemany R, Fueyo J. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res 12(2):556-62, 1/2006. PMID: 16428500.
26. Guo W, Zhu H, Zhang L, Davis J, Teraishi F, Roth JA, Stephens C, Fueyo J, Jiang H, Conrad C, Fang B. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 13(1):82-90, 2006. PMID: 16037823.
27. Alonso MM, Fueyo J, Shay JW, Aldape KD, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. J Natl Cancer Inst 97(21):1589-600, 11/2005. PMID: 16264179.
28. Jiang H, Alemany R, Gomez-Manzano C, Medrano DR, Lemoine MG, Olson MV, Alonso MM, Lee OH, Conrad CC, Yung WK, Fueyo J. Downmodulation of E1A protein expression as a novel strategy to design cancer-selective adenoviruses. Neoplasia 7(8):723-9, 8/2005. PMID: 16207474.
29. Conrad C, Miller CR, Ji Y, Gomez-Manzano C, Bharara S, McMurray JS, Lang FF, Wong F, Sawaya R, Yung WK, Fueyo J. Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12(3):284-94, 3/2005. PMID: 15650766.
30. Jiang H, Gomez-Manzano C, Alemany R, Medrano D, Alonso M, Bekele BN, Lin E, Conrad CC, Yung WK, Fueyo J. Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas. Neoplasia 7(1):48-56, 2005. PMID: 15720816.
31. Stolarek R, Gomez-Manzano C, Jiang H, Suttle G, Lemoine MG, Fueyo J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 11(11):713-20, 11/2004. PMID: 15332115.
32. Gomez-Manzano C, Balague C, Alemany R, Lemoine MG, Mitlianga P, Jiang H, Khan A, Alonso M, Lang FF, Conrad CA, Liu TJ, Bekele BN, Yung WK, Fueyo J. A novel E1A-E1B mutant adenovirus induces glioma regression in vivo. Oncogene 23(10):1821-8, 3/2004. PMID: 15014451.
33. Arap MA, Lahdenranta J, Hajitou A, Marini FC, 3rd, Wood CG, Wright KC, Fueyo J, Arap W, Pasqualini R. Model of unidirectional transluminal gene transfer. Mol Ther 9(2):305-10, 2/2004. PMID: 14759814.
34. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA, Liu TJ, Jiang H, Lemoine MG, Suzuki K, Sawaya R, Curiel DT, Yung WK, Lang FF. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 95(9):652-60, 5/2003. PMID: 12734316.
35. Gomez-Manzano C, Fueyo J, Jiang H, Glass TL, Lee HY, Hu M, Liu JL, Jasti SL, Liu TJ, Conrad CA, Yung WK. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann Neurol 53(1):109-17, 2003. PMID: 12509854.
36. Mitlianga PG, Gomez-Manzano C, Kyritsis AP, Fueyo J. Overexpression of E2F-1 leads to bax-independent cell death in human glioma cells. Int J Oncol 21(5):1015-20, 11/2002. PMID: 12370749.
37. Lamfers ML, Grill J, Dirven CM, Van Beusechem VW, Geoerger B, Van Den Berg J, Alemany R, Fueyo J, Curiel DT, Vassal G, Pinedo HM, Vandertop WP, Gerritsen WR. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 62(20):5736-42, 10/2002. PMID: 12384532.
38. Adachi Y, Chandrasekar N, Kin Y, Lakka SS, Mohanam S, Yanamandra N, Mohan PM, Fuller GN, Fang B, Fueyo J, Dinh DH, Olivero WC, Tamiya T, Ohmoto T, Kyritsis AP, Rao JS. Suppression of glioma invasion and growth by adenovirus-mediated delivery of a bicistronic construct containing antisense uPAR and sense p16 gene sequences. Oncogene 21(1):87-95, 1/2002. PMID: 11791179.
39. Calbo J, Marotta M, Cascallo M, Roig JM, Gelpi JL, Fueyo J, Mazo A. Adenovirus-mediated wt-p16 reintroduction induces cell cycle arrest or apoptosis in pancreatic cancer. Cancer Gene Ther 8(10):740-50, 10/2001. PMID: 11687897.
40. Gomez-Manzano C, Mitlianga P, Fueyo J, Lee HY, Hu M, Spurgers KB, Glass TL, Koul D, Liu TJ, McDonnell TJ, Yung WK. Transfer of E2F-1 to human glioma cells results in transcriptional up-regulation of Bcl-2. Cancer Res 61(18):6693-7, 9/2001. PMID: 11559537.
41. Gomez-Manzano C, Lemoine MG, Hu M, He J, Mitlianga P, Liu TJ, Yung AW, Fueyo J, Groves MD. Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU. Int J Oncol 19(2):359-65, 8/2001. PMID: 11445852.
42. Im SA, Kim JS, Gomez-Manzano C, Fueyo J, Liu TJ, Cho MS, Seong CM, Lee SN, Hong YK, Yung WK. Inhibition of breast cancer growth in vivo by antiangiogenesis gene therapy with adenovirus-mediated antisense-VEGF. Br J Cancer 84(9):1252-7, 5/2001. PMID: 11336478.
43. Mitlianga PG, Kyritsis AP, Gomez-Manzano C, Lemoine MG, Hu M, Liu TJ, Yung WK, Fueyo J. Co-expression of E2F-2 enhances the p53 anti-cancer effect in human glioma cells. Int J Oncol 18(2):343-7, 2/2001. PMID: 11172602.
44. Suzuki K, Fueyo J, Krasnykh V, Reynolds PN, Curiel DT, Alemany R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 7(1):120-6, 2001. PMID: 11205899.
45. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19(1):2-12, 1/2000. PMID: 10644974.
46. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, Yung WK. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Research 59(4):895-900, 2/1999. PMID: 10029081.
47. Ke LD, Fueyo J, Chen X, Steck PA, Shi YX, Im SA, Yung WK. A novel approach to glioma gene therapy: down-regulation of the vascular endothelial growth factor in glioma cells using ribozymes. Int J Oncol 12(6):1391-6, 6/1998. PMID: 9592205.
48. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, McDonnell TJ, Shi X, Rao JS, Levin VA, Kyritsis AP. Overexpression of E2F-1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo. Nat Med 4(6):685-90, 6/1998. PMID: 9623977.
49. Fueyo J, Gomez-Manzano C, Yung WK, Liu TJ, Alemany R, Bruner JM, Chintala SK, Rao JS, Levin VA, Kyritsis AP. Suppression of human glioma growth by adenovirus-mediated Rb gene transfer. Neurology 50(5):1307-15, 5/1998. PMID: 9595979.
50. Fueyo J, Gomez-Manzano C, Puduvalli VK, Martin-Duque P, Perez-Soler R, Levin VA, Yung WK, Kyritsis AP. Adenovirus-mediated p16 transfer to glioma cells induces G1 arrest and protects from paclitaxel and topotecan: implications for therapy. Int J Oncol 12(3):665-9, 3/1998. PMID: 9472109.
51. Chintala SK, Fueyo J, Gomez-Manzano C, Venkaiah B, Bjerkvig R, Yung WK, Sawaya R, Kyritsis AP, Rao JS. Adenovirus-mediated p16/CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene 15(17):2049-57, 10/1997. PMID: 9366522.
52. Gomez-Manzano C, Fueyo J, Kyritsis AP, McDonnell TJ, Steck PA, Levin VA, Yung WK. Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. J Natl Cancer Inst 89(14):1036-44, 7/1997. PMID: 9230885.
53. Fueyo J, Gomez-Manzano C, Bruner JM, Saito Y, Zhang B, Zhang W, Levin VA, Yung WK, Kyritsis AP. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas. Oncogene 13(8):1615-9, 10/1996. PMID: 8895506.
54. Gomez-Manzano C, Fueyo J, Kyritsis AP, Steck PA, Roth JA, McDonnell TJ, Steck KD, Levin VA, Yung WK. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res 56(4):694-9, 2/1996. PMID: 8630997.
55. Fueyo J, Gomez-Manzano C, Yung WK, Clayman GL, Liu TJ, Bruner J, Levin VA, Kyritsis AP. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogene 12(1):103-10, 1/1996. PMID: 8552379.
56. Fueyo J, Gomez-Manzano C, Yung WK, Zhang W, Lee PS, Majumder S, Perhouse M, Levin VA, Kyritsis AP. A frequent polymorphism in exon 1 of the p16/CDKN2 gene. Mol Cell Probes 9(6):465-6, 12/1995. PMID: 8808318.
57. EAFT Study Group. Silent brain infartaction in nonrheumatic atrial fibrillation. Neurology 46:159-165, 1995.
58. Fueyo J, Ferrer I, Valldeoriola F, Graus F. The expression of a neuronal nuclear antigen (Ri) recognized by the human anti-Ri autoantibody in the developing rat nervous system. Neurosci Lett 162(1-2):141-4, 11/1993. PMID: 8121617.
59. Escudero D, Barnadas A, Codina M, Fueyo J, Graus F. Anti-Ri-associated paraneoplastic neurologic disorder without opsoclonus in a patient with breast cancer. Neurology 43(8):1605-6, 8/1993. PMID: 8351021.
60. Graus F, Rowe G, Fueyo J, Darnell RB, Dalmau J. The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. Neurosci Lett 150(2):212-4, 2/1993. PMID: 8469424.
61. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 333:5-10, 1993.
62. EAFT Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342:1255-1262, 1993.
63. Pou Serradell A, Fueyo J, Gomez C, Oliveras C, Espadaler JM, Alameda F, Graus F. [Paraneoplastic encephalomyelitis and Lambert-Eaton syndrome]. Rev Neurol (Paris) 148(10):605-9, 1992. PMID: 1338234.

Invited Articles

1. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Cho. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8(4):445-544, 4/2012. PMCID: PMC3404883.
2. Fueyo J, Gomez-Manzano C, Yung WK. Advances in Translational Research in Neuro-Oncology. Arch Neurol 68(3):303-8, 3/2011. e-Pub 11/2010. PMCID: PMC3109723.
3. Jiang H, Martin V, Alonso M, Gomez-Manzano C, Fueyo J. RB-E2F1: Molecular rheostat for autophagy and apoptosis. Autophagy 6(8):1216-7, 11/2010. e-Pub 11/2010. PMID: 20935482.
4. Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses for the treatment of brain tumors. Curr Opin Mol Ther 12(5):530-7, 10/2010. PMID: 20886384.
5. Jiang H, Fueyo J. Eradication of brain tumor stem cells with an oncolytic adenovirus. Discov Med 10(50):24-8, 7/2010. PMID: 20670595.
6. Klionsky DJ, Codogno P, Cuervo AM, Deretic V, Elazar Z, Fueyo-Margareto J, Gewirtz DA, Kroemer G, Levine B, Mizushima N, Rubinsztein DC, Thumm M, Tooze SA. A comprehensive glossary of autophagy-related molecules and processes. Autophagy 6(4):438-448, 5/2010. PMID: 20484971.
7. Jiang H, Gomez-Manzano C, Lang F, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 9(5):422-7, 10/2009. PMID: 19860656.
8. Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C. E2F1 in gliomas: A paradigm of oncogene addiction. Cancer Lett 263(2):157-63, 5/2008. e-Pub 3/2008. PMID: 18334281.
9. Jiang H, White EJ, Gomez-Manzano C, Fueyo J.. Adenovirus's last trick: you say lysis, we say autophagy. Autophagy 4(1):118-20, 1/2008. e-Pub 11/2007. PMID: 18032923.
10. Klionsky DJ, Fueyo J.. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4(2):151-75, 2008. e-Pub 11/2007. PMCID: PMC2654259.
11. Gomez-Manzano C, Alonso M, Jiang H, Fueyo J.. Interspecies adenovirus fiber shows "evolutionary" advantage for oncolytic therapy of gliomas. Cancer Biol Ther 11(7):794-6, 2008. PMID: 18756625.
12. Martin V, Liu D, Fueyo J, Gomez-Manzano C.. Tie2: a journey from normal angiogenesis to cancer and beyond. Histol Histopathol. 23:773-80, 2008. PMID: 18366015.
13. Jiang H, Alonso MM, Gomez-Manzano C, Piao Y, Fueyo J. Oncolytic viruses and DNA-repair machinery: overcoming chemoresistance of gliomas. Expert Rev Anticancer Ther 6:1585-92, 11/2006. PMID: 17134363.
14. Alonso MM, Fueyo J, Yung WK, Gomez-Manzano C. E2F1 and telomerase: alliance in the dark side. Cell Cycle 5(9):930-5, 5/2006. PMID: 16628012.
15. Jiang H, McCormick F, Lang FF, Gomez-Manzano C, Fueyo J. Oncolytic adenoviruses as antiglioma agents. Expert Rev Anticancer Ther 6(5):697-708, 5/2006. PMID: 16759161.
16. Gomez-Manzano C, Yung WK, Alemany R, Fueyo J. Genetically modified adenoviruses against gliomas: from bench to bedside. Neurology 63(3):418-26, 8/2004. PMID: 15304571.
17. Jiang H, Conrad C, Fueyo J, Gomez-Manzano C, Liu TJ. Oncolytic adenoviruses for malignant glioma therapy. Front Biosci 8:d577-88, 5/2003. PMID: 12700119.
18. Alemany R, Gomez-Manzano C, Fueyo J. [Oncolytic adenovirus for the treatment of cerebral tumors: past, present and future]. Neurologia 16(3):122-7, 3/2001. PMID: 11333782.
19. Fueyo J, Gomez-Manzano C, Liu TJ, Yung WK. Delivery of cell cycle genes to block astrocytoma growth. J Neurooncol 51(3):277-87, 2/2001. PMID: 11407598.
20. Alemany R, Gomez-Manzano C, Balague C, Yung WK, Curiel DT, Kyritsis AP, Fueyo J. Gene therapy for gliomas: molecular targets, adenoviral vectors, and oncolytic adenoviruses. Exp Cell Res 252(1):1-12, 10/1999. PMID: 10502394.
21. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. Targeting in gene therapy for gliomas. Arch Neurol 56(4):445-8, 4/1999. PMID: 10199333.
22. Gomez-Manzano C, Fueyo J, Alameda F, Kyritsis AP, Yung WK. Gene therapy for gliomas: p53 and E2F-1 proteins and the target of apoptosis. Int J Mol Med 3(1):81-5, 1999. PMID: 9864390.
23. Fueyo J, Gomez-Manzano C. Molecular control of the cellular cycle and apoptosis: new treatments for gliomas. Neurologia 8:43-47, 1999.
24. Fueyo J, Gomez-Manzano C, Yung WK, Kyritsis AP. The functional role of tumor suppressor genes in gliomas: clues for future therapeutic strategies. Neurology 51(5):1250-5, 11/1998. PMID: 9818841.
25. Fueyo J, Gomez-Manzano C. [Molecular control of the cellular cycle and apoptosis: new treatments for gliomas]. Neurologia 13(7):349-55, 8/1998. PMID: 9810797.

Abstracts

1. Fueyo J, Gomez-Manzano C, Yung WKA, Conrad C, Lang F. Continuous development of delta-24-rgd for the treatment of gliomas. Paper presented at: 8th International Conference on Brain Tumor Research and Therapy, 5/2010.
2. Alonso M, Gomez-Manzano C, Vaillant B, Xu J, Liu D, Jiang H, White EJ, Colman H, Fueyo J. Salinomycin displays more potent anticancer effect against brain tumor stem cells than temozolomide. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR (#3340), 4/2010.
3. Fueyo J. Successful developmental pathway of Delta-24-RGD. In: Proceedings of the 2009 NCI Translational Science Meeting (TSM 2); 2009 Nov 5-7; Vienna, VA, 11/2009.
4. White EJ, Jiang H, Xu J, Gomez-Manzano C, Fueyo J. Involvement of autophagy in oncolysis: E1A is required but not sufficient. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; (#774), 4/2009.
5. White E, Jiang H, Alonso M, Piao Y, Xu J, Conrad C, Yung WKA, Gomez-Manzano C, Fueyo J. Atg5 is required for adenovirus-induced autophagy in cancer cells. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA (#3357), 4/2008.
6. Jiang H, Xu J, Lang F, Colman H, Gomez-Manzano C, Bogler O, Latha K, Yung WKA, Fueyo J. Delta-24-RGD induces autophagy in brain tumor stem cells and prolongs survival in glioma-bearing mice. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA (#3304), 4/2008.
7. Alonso M, Gomez-Manzano C, Jiang H, Martin V, Liu D, Xu J, Yung WKA, Gilbert M, Fueyo J. Role of the silencing of the MGMT promoter in the therapeutic synergy between Delta-24-RGD and temozolomide. 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA (#1364), 4/2008.
8. Alonso M, Gomez-Manzano C, Jiang H, Xu J, Piao Y, Yokoyama T, Kondo S, Yung WKA, Fueyo J. Delta-24-RGD in combination with RAD001 induces autophagic cell death and 80% long-term survivors. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 9(4):491 (#ET-36), 10/2007.
9. Yong R, Fueyo J, Marini F, Hata N, Gumin J, Andreef M, Lang F. Human bone marrow-derived mesenchymal stem cells as delivery vehicles for oncolytic adenovirus Delta-24-RGD in the treatment of malignant glioma. 12th Annual Meeting of the Society for Neuro-Oncology (SNO); In: Neuro Oncol 9(4):591 (#SC-05), 10/2007.
10. Jiang H, Gomez-Manzano C, Yokoyama T, Alonso M, Kondo S, Xu J, Bekele BN, Colman H, Lang F, Fueyo J. Oncolytic adenovirus Delta-24-RGD induces efficacious antiglioma activity in brain tumor stem cell models. 12th Annual Meeting of the Society for Neuro-Oncology (SNO), In: Neuro Oncol 9(4):496 (#ET-51), 10/2007.
11. Jiang H, Olson MV, Xu J, Lee OH, Piao Y, Yung WKA, Fueyo J. Exportin 1-mediated nuclear export of adenovirus E1A protein: a novel target for generation of oncolytic viruses. Proc Amer Assoc Cancer Res 47:702-a (#2981), 4/2006.
12. Andreeff M, Dembinski J, Studeny M, Ling X, Cabreira-Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin RE, Marini FC. Mesenchymal stem cells: Precursors for tumor stroma and targeted delivery vehicles for anticancer agents. Proc Amer Assoc Cancer Res 47:238-b (#1008), 4/2006.
13. Jiang H, Medrano D, Gomez-Manzano C, LeMoine M, Alemany R, Olson M, Alonso M, Conrad C, Yung WKA, Fueyo J. Downmodulation of E1A Protein Expression as a Novel Strategy to Design Cancer Selective Adenoviruses. 96th Annual Meeting, American Associate for Cancer Research, Anaheim, CA, 4/2005.
14. Olson MV, Alonso M, Medrano D, Sheng X, Gomez-Manzano C, Jiang H, Yung WKA, Fueyo J. E2F1 transcriptionally activates PTEN. 96th Annual Meeting, American Associate for Cancer Research, Anaheim, CA, 4/2005.
15. Andreeff M, Dembinski J, Studeny M, Ling X, Hansen M, Zompetta C, McQueen T, Fueyo J, Champlin R, Marini F. Mesenchymal progenitor cells as gene delivery systems for cancer therapy: Tropism and efficacy. Proc Amer Assoc Cancer Res 46:1254 (#5302), 4/2005.
16. Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Oncolytic adenovirus Icovir-2 shows improved therapeutic index than D24-RGD for glioma. 96th Annual Meeting, American Associate for Cancer Research, Anaheim, CA, 4/2005.
17. Olson M, Medrano D, Jiang H, Gomez-Manzano C, Alonso M, Aldape K, Price R, Yung WKA, Fueyo J . Developmental abnormalities and oncogenesis in the brain of a transgenic E2F1 mouse model. Neuro-Oncology 7:289, 2005.
18. Olson M, Jiang H, Medrano D, Gomez-Manzano C, Aldape K, Fueyo J. GFAP-E2F1 transgenic mouse provides the first evidence of an oncogenic role of E2F1 in brain tumor formation. Keystone Conferences: Cellular Senescence and Cell Death, Keystone, CO, 2005.
19. Alonso M, Alemany R, Gomez-Manzano C, Yung WKA, Jiang H, Fueyo J. Icovir-2, an old friend with a new face: E2F-1 mediated glioma selectivity for Delta24-RGD. Neuro-Oncology 7:377, 2005.
20. Jiang H, Alemany R, Gomez-Manzano C, Yung WKA, Sawaya R, Lang F, Fueyo J. Comparison of the Antiglioma Effect of E1A and E1B-55kD-Mutant Oncolytic Adenoviruses. AANS/CNS Section on Tumors Sixth Biennial Satellite Symposium, San Francisco, CA, 10/2004.
21. Alonso MM, Fueyo J. Direct regulation of telomerase activity by E2F1 in cancer and normal cells. EMBO Workshop / 58th Harden Conference-Telomeres and Genome Stability, Cambridge, UK, 5/2004.
22. Medrano D, Jiang H, Gomez-Manzano C, Olson M, Lemoine M, Yung WKA, Fueyo J. Replication-competent adenoviruses with impaired p300/CBP binding express low E1A protein levels: implications for oncolytic therapy. 8th Annual Trainee Recognition Day and Research Exposition, The University of Texas M. D. Anderson Cancer Center, Houston, 5/2004.
23. Alonso MM, Gomez-Manzano C, Aldape K, Jiang H, Xu J, Kondo Y, Fueyo J. E2F1 upregulates telomerase: cell-cycle related telomerase activity in sarcoma cells. 95th Annual Meeting, American Association for Cancer Research, Orlando, FL, 3/2004.
24. Gomez-Manzano C, Xu J, Fueyo J, Aldape KD, Bekele BN, Lemoine MN, Fuller GN and Yung WKA. Significant correlation of Angiopoietin-2 and Nestin expression in glioblastomas. Proc Amer Assoc Cancer Res 45:830 (#3599), 3/2004.
25. Jiang H, Gomez-Manzano C, Medrano D, Cass A, Alonso M, Alemany R, Yung WKA, Fueyo J. The level of E1A as a factor for tumor selectivity in oncolytic adenoviruses. 95th Annual Meeting, American Association for Cancer Research, Orlando, FL, 3/2004.
26. Andreeff M, Studeny M, Dembinski J, Cabreira-Hansen M, Zompetta C, Yang HY, McQueen T, Fueyo J, Champlin RE, Pasqualini R, Lang F, Marini FC,. Mesenchymal progenitor cells as gene delivery systems for cancer and leukemia therapy. Proc Amer Assoc Cancer Res 45:1304-a (#BA-2), 2004.
27. Medrano D, Jiang H, Johnson D, Aldape K, Olson M, Gomez-Manzano C, Fueyo J. Transgenic overexpression of E2F1 in the brain in E2F4 null background results in severe hydrocephalus similar to E2F5 null mice. Special AACR Conference on Cell Cycle and Cancer: Pathways and Therapies, Fort Lauderdale, FL, 2004.

Book Chapters

1. Gomez-Manzano C, Fueyo J, Kyritsis AP, Yung WKA. Tumor suppressor gene therapy for brain tumors. In: Gene Therapy for Neurological Disorders & Brain Tumors. Ed(s) EA Chiocca, XO Breakfield. Humana Press Inc: Totowa, NJ, 205-230, 1998. ISBN: 0896035077, 978-0896035072.
2. Gomez-Manzano C, Lee O-H, Xu J, Fueyo J, Yung WKA. Neovascularization of malignant gliomas. In: Molecular Neuro-Oncology: Gliomas Methods and Protocols, In series: Methods in Molecular Medicine. Ed(s) W Debinski, GY Gillespie. Humana Press Inc, 2000.
3. Gomez-Manzano C, Fueyo J, Yung WKA. Gene therapy approaches for gliomas. In: Brain Cancer. In series: American Cancer Society Atlas of Clinical Oncology. Ed(s) Prados. BC Decker, 219-237, 2001. ISBN: 1550090984, 978-1550090987.
4. Stolarek R, Fueyo J, Gomez-Manzano C, Jiang H, Yung WKA. Gene-Based Therapy for Gliomas: Targeting the Cancer Genome. In: Genomic and Molecular Neuro-Oncology. Ed(s) W Zhang, GN Fuller. Jones and Bartlett Publishers, Inc., 283-302, 2003. ISBN: 0763722618, 9780763722616.
5. Fueyo J, Gomez-Manzano C, McDonnell TJ. Cell Cycle and Apoptosis in Human Brain Tumors. In: Human Brain Tumors. Humana Press Inc., 2005.
6. Fueyo J, Gomez-Manzano C, McDonnell TJ. Regulation of Cell-Cycle and Apoptosis in Human Brain Tumors. In: Brain Tumors. In series: Contemporary Cancer Research, Part II. Ed(s) F Ali-Osman. Humana Press Inc: Totowa, NJ, 249-264, 2005. ISBN: 978-1-58829-042-7 (Print) 978-1-59259-843-4 (Online).
7. Jiang H, McCormick F, Gomez-Manzano C, Curiel DT, Lang FF, Yung WKA, Fueyo J. Replicating viruses for brain tumor treatment. In: Gene Therapy for Neurological Disorders. Ed(s) MG Castro, PR Lowenstein. BC Decker Inc: New York, 293-326, 2006.
8. Alonso MM, Gomez-Manzano C, Alemany R, Jiang H, McCormick F, Fueyo J. Conditionally replicative adenoviruses as antitumoral agents: Past, present and future. In: Cancer and Gene Therapy. Ed(s) PL Hermonat. Transworld Research Network: Kerala, India, 41-54, 2007. ISBN: 8178952521, 978-8178952529.
9. Jiang H, White EJ, Conrad C, Gomez-Manzano C, Fueyo J. Autophagy pathways in glioblastoma. In: Methods Enzymology: Autophagy in Disease and Clinical Applications. 453, Part C. Ed(s) DL Klionsky. Academic Press: United States, 273-86, 2009. ISBN: 9780123743107.
10. Alonso MM, Fueyo J, Johnson DG, Gomez-Manzano C. The oncogenic role of E2F1 in brain tumors. In: Control of Cellular Physiology by E2F Transcription Factors. Ed(s) K Yoshida. Research Signpost: Kerala, 257-270, 2008. ISBN: 978-81-308-0230-5.
11. Gomez-Manzano C, Jiang H, Alonso M, Yung WK, Fueyo J. Gene Therapy. In: Handb Clin Neurol. 104, 3rd. Ed(s) W Grisold, R Siffietti. Elsevier: Edinburgh, UK, 331-8, 2012. ISBN: 22230451.
12. Alonso M, Fueyo J, Gomez-Manzano C. Malignant Gliomas: Role of E2F1 Transcription Factor. In: Tumors of the Central Nervous System. Volume 1. Ed(s) MA Hayat. Springer. In Press.
13. Jiang H, Fueyo J. Gene Therapy of Brain Tumors. In: Gene-based Therapies for Cancer, 1st. Ed(s) J Roth. Springer Science + Business Media and Humana Press, 17-32, 2010.
14. Alonso MM, Jiang H, Gomez-Manzano C, Fueyo J. Targeting Brain Tumor Stem Cells with Oncolytic Adenoviruses. In: Methods Mol Biol. 797. Springer Science & Humana Press, 111-25, 2012. PMCID: PMC3397800.

Letters to the Editor

1. Fueyo J, Gomez-Manzano C, Pascual J, Pou A. Paraneoplastic syndromes. Neurology 43:236, 1993.

Last updated: 10/15/2013